Explained risk from apoB-containing lipoproteins to MI - PACE-CME

Explained risk from apoBcontaining lipoproteins to MI

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC.25
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
- Darren K. McGuire, MD
Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
AHA 2024
Bempedoic acid reduces adverse limb events in patients with PAD
- Marc Bonaca, MD
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
AHA 2024
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA